CE&B ROUNDS

Presents

Eva Lonn
MD MSc FRCPC FACC
***
Professor of Medicine, Division of Cardiology
****
Senior Scientist,
Population Health Research Institute
****
Cardiologist, Hamilton Health Sciences

Novel Approaches in primary Cardiovascular Disease Prevention: the HOPE-3 Trial

HOPE-3 is a large international multi-center randomized controlled trial of blood pressure and cholesterol lowering in intermediate risk persons without cardiovascular disease. The trial evaluated participants from 21 countries and used several novel approaches, such as the lack of strict blood pressure of cholesterol entry levels with enrolment based on the “uncertainty principle”, the factorial design with comparisons at the margins of the factorial but also prespecified comparisons of the diagonal cells (double active vs. double placebo) and streamlined monitoring. The results of the HOPE-3 trial are expected to have an important impact on primary cardiovascular disease prevention globally.

Dr. Lonn is a Professor of Medicine at McMaster University, Senior Scientist at the Population Health Research Institute and was the Director of the Vascular Research Imaging Laboratory at the Population Health Research Institute for many years. Her research interests are in epidemiology and clinical trials in cardiovascular prevention and in ultrasound imaging in atherosclerosis. She has received numerous peer reviewed grants and industry contracts and has led several large international clinical trials in cardiovascular prevention and in atherosclerosis as Principal Investigator and/or member of the Steering Committee of large international trials in cardiovascular prevention and atherosclerosis imaging.